---
schema_version: "secwatch.filing_event.v1"
accession: "0001819790-22-000045"
form_type: "8-K"
ticker: "TARS"
cik: "0001819790"
company_name: "Tarsus Pharmaceuticals, Inc."
filed_at: "2022-12-07T23:59:59+00:00"
generated_at: "2026-06-21T08:16:45.010937+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Tarsus Pharma board chair Ackermann resigns; CEO Azamian succeeds; Yarno named lead independent director

## Summary
- Michael Ackermann resigned as Chairperson and Board member effective Dec 2, 2022; no disagreement with company.
- Ackermann entered a 12-month consulting agreement, receiving 5,000 RSUs vesting in one year and continued equity vesting.
- CEO Bobak Azamian appointed Board Chairperson effective Dec 2; will not receive additional compensation.
- Wendy Yarno appointed Lead Independent Director effective Dec 2; granted 5,000 RSUs vesting in one year and $75,000 annual cash retainer.

## SEC filing metadata
- accession: 0001819790-22-000045
- form_type: 8-K
- ticker: TARS
- cik: 0001819790
- company_name: Tarsus Pharmaceuticals, Inc.
- filed_at: 2022-12-07T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819790/000181979022000045/0001819790-22-000045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819790/000181979022000045/tars-20221201.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001819790-22-000045
- JSON: https://secwatch.observer/filing/0001819790-22-000045.json
- Plain text: https://secwatch.observer/filing/0001819790-22-000045.txt

## Key facts
- Executive change
  Michael Ackermann resigned as Chairperson of the Board at Tarsus Pharmaceuticals, Inc..
  - Action: resigned
  - Role: Chairperson of the Board
  source text: Michael Ackermann, the Chairperson of the Board of Directors (the “Board”) of Tarsus Pharmaceuticals, Inc. (the “Company”) notified the Company of his resignation as the Chairperson and as a member of the Board and any committees of the Board, effective December 2, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819790/000181979022000045/0001819790-22-000045-index.htm
- Executive change
  Wendy Yarno was appointed as Lead Independent Director at Tarsus Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Lead Independent Director
  source text: and Wendy Yarno, current member of the Board, as Lead Independent Director, each appointment effective as of December 2, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819790/000181979022000045/0001819790-22-000045-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.